M.B.A., Haas School of Business, University of California, Berkeley; Ph.D., molecular biology, University of California, San Diego; B.S., biochemistry, University of California, Los Angeles
Summary of Experience
Dr. Nellesen has broad experience in consulting, applying a range of strategies that address client needs in the development and commercialization of products for the biotechnology, pharmaceutical, molecular diagnostic, and medical device industries. He specializes in value proposition and evidence strategy, helping clients develop clinical and economic evidence of value to support launch strategy and secure favorable reimbursement. This work often includes published or unpublished evidence of the value of new products, including evidence dossiers (global value dossiers or AMCP dossiers) and related payer communication tools, health economic models, and peer-reviewed studies. He has also assisted clients in conducting primary research with payers and other stakeholders to assess the value of new technologies and evidence needed for favorable market access. In more than 15 years working in the biopharmaceutical industry, Dr. Nellesen has led a range of commercial strategy engagements, including strategic planning, intellectual property management and valuation, health care compliance, and business process improvement. Prior to joining Analysis Group, Dr. Nellesen worked as a consultant at PRTM and as a scientist and patent portfolio manager at Incyte Pharmaceuticals.